NCT03945305 Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
| NCT ID | NCT03945305 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yi Yang |
| Condition | Essential Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-11-25 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2023-11-25 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
Eligibility Criteria
Inclusion Criteria: 1. Age≥30 years, ≤ 75 years, regardless of sex; 2. Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment. 3. Signed and dated informed consent is obtained. Exclusion Criteria: 1. Blood pressure ≥ 180/110mmHg; 2. Planned adjustment of antihypertensive drugs within the next 3 weeks; 3. Severe hematologic disorders or significant coagulation abnormalities; 4. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 5. Pregnant or lactating women; 6. Severe hepatic and renal dysfunction; 7. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; 8. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03945305 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 75 Years, studying Essential Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03945305 currently recruiting?
Yes, NCT03945305 is actively recruiting participants. Contact the research team at doctor_yangyi@163.com for enrollment information.
Where is the NCT03945305 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT03945305 clinical trial?
NCT03945305 is sponsored by Yi Yang. The trial plans to enroll 500 participants.